Jordan Gainey

Radiation Oncologist in SC

[Bobby Koneru, MD @KoneruMd]

🚨The first American guidelines for low-dose radiotherapy in osteoarthritis were just published.

That’s not a small thing.

For decades, European centers have been treating OA with low-dose RT. American patients largely couldn’t access it. No formal guidance. No insurer framework. No roadmap for referring providers.

That changes today.

The American Radium Society Appropriate Use Criteria, published in the American Journal of Clinical Oncology, define exactly when and how to use LDRT for OA. Radiation oncologists, rheumatologists, physiatrists, and orthopedic surgeons built this together.

For insurers, this is the clinical framework they’ve been waiting for.

Honored to be a co-author alongside the global experts who made this possible.

[Rashid K. Sayyid @RKSayyid]

PSMAddition: Ph 3 trial of ¹⁷⁷Lu-PSMA-617 + ADT/ARPI in PSMA+ mHSPC (n=1,144)

🚨 PSA Endpoints 🚨

Primary endpoint:
🔹rPFS: HR 0.72 (95% CI 0.58-0.90; p=0.002)

PSA endpoints:
🔹PSA90 at any time: 89.5% vs 85.6%
🔹PSA <0.2 ng/mL at 48 wks: 87.4% vs 74.9%
🔹PSA <0.02 ng/mL at 48 wks: 65.3% vs 46.7%
🔹Time to PSA progression: HR 0.42 (95% CI 0.30-0.59)

Adding ¹⁷⁷Lu-PSMA-617 increased the frequency and depth of PSA responses and reduced the risk of PSA progression by 58%

@urotoday
#AUA26

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

My @ASTRO_org 2026 GU spring refresher extended "long-course" slide deck is available at
https://t.co/HND3LmzgZb

You can also watch the "short-course" 1.5 hour narrated version here:
https://t.co/GpDtfapF4K

[Daniel E Spratt @DrSpratticus]

@APCCC_Lugano #APCCC26 @US_FDA @DrMakaryFDA

This is very important for patients, providers, and regulators to understand. ICECAP showed MFS by conventional imaging is a surrogate endpoint (strong correlation to OS treatment effects and high surrogate threshold effect (STE)).

However, multiple groups have shown that event-free survival (EFS) very closely mirrors PSMA PET/CT MFS. Thus, use of EFS or PET defined MFS have very poor correlation to OS, very low STE, making it nearly impossible for any trial to have a HR low enough for it to serve as a surrogate endpoint for OS.

I hope @DrMakaryFDA and FDA appreciate this. Inhibiting AR will nearly ALWAYS lower PSA. Thus, testoerone suppressed for prolonged period you will near always improve BCR --> EFS --> PSMA PET defined MFS. None of that means you improved outcomes or survival.

@ZEROCancer @PCF_Science

[Piet Ost @piet_ost]

1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.

[Julian Chavarriaga @chavarriagaj]

#SUO25 📢TiP: IDeate-Prostate01
🧪 I-DXd (B7-H3 ADC) vs docetaxel in post-ARPI mCRPC
👥 ~1,440 pts | 1–2 prior ARPIs | global phase 3
🔹 Dual primary: OS & rPFS
🔹 Stratified by mets pattern, B7-H3 level, prior PSMA Tx
✅ Targeting B7-H3: novel ADC with promising early signals
@UroToday @UroOnc

[Zach Klaassen @zklaassen_md]

⚡️ #SUO25 LBA - Neo-SAbR: Ph II Trial of Neoadj SABR to IVC TT in RCC @urotoday @UTSWUrology

🌞n=23, neoadjv 40 Gy/5 fr or 36 Gy/3 fr SABR
🌞Prim EP (+ve trial): 1-yr RFS @ 12 mo: 71.4% (80%CI 56.6–82.0%; p=0.087)
🌞TT ⬇️staging: 22.7%
🌞0 RT Gr 4+ AEs
🌞36.4% periop Gr 3+ AEs

[ASTRO @ASTRO_org]

New research from @jsunny99 @thayerschool reveals FLASH radiotherapy's normal tissue sparing effect requires sequential deliveries to be within ~10s—matching tissue reoxygenation time. Split-dose study provides key evidence linking oxygen dynamics to the FLASH effect. Read about it in the #RedJournal: https://t.co/D0nYc9Pdti

[Uğur Özkerim @UOzkerim]

💥 The @OncoAlert #GUOncology team has once again delivered an outstanding lineup! 🙌
Excited to discuss these studies live at #ESMO25 Berlin 🇩🇪
From PSMAaddition to RAMPART and KEYNOTE-905, the GU field is stronger than ever.
Which one are you most looking forward to? 💬

🌍 Follow the global dream team:

#OncoAlertAF
🇺🇸 @WeOncologists
🇧🇪 @ElisaAgostinett
🇦🇷 @nataliagandur
🇮🇹 @to_be_elizabeth
🇫🇷 @acampsmalea
🇺🇸 @BRicciutiMD
🇯🇵 @HHorinouchi
🇺🇸 @Abdallah81MD
🇧🇷 @bavilima
🇧🇷 @FernandoOnco
🇺🇸 @realbowtiedoc
🇹🇷 @Erman_Akkus
🇮🇹 @Lucarecco
🇮🇹 @GaiaGriguolo
🇷🇸 @JankovicK
🇪🇸 @MarioBalsaMD
🇪🇸 @DrMirallas
🇺🇸 @GIMedOnc 
🇹🇷 @UOzkerim
🇮🇳 @DrRishabhOnco
🇲🇽 @ReginaBarCar

[Urology Times @UrologyTimes]

The phase 3 PSMAddition trial has met its primary end point, showing that lutetium (177Lu) vipivotide tetraxetan plus SOC significantly improved rPFS vs SOC alone in patients with PSMA-positive mHSPC. #pcsm
https://t.co/a2B2K9OmMh

[Aman Chauhan @AmanChauhanMD]

Check out the latest @ASCO guidelines on functional NETs. While management of well-differentiated NETs is often nuanced, three critical factors should be assessed at the initial visit to guide an effective treatment plan:
1.Tumor Grade
2.Disease Stage
3.Functional Status

➡️https://t.co/njC71shyL1

[Joe Y Chang @JoeChangMD]

Re-irradiation is common but challenging in lung cancer.
ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary.
My personalized Share Link:
https://t.co/S7o0VY2kUo

[Duke Radiation Oncology @DukeRadOnc]

New @JCO_ASCO publication featuring @DukeCancer #RadOnc authors: "Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment" – congrats! 🔗https://t.co/9ezQMevBnd

[Gustavo @gusviani]

Meningioma Grading Will Never Be the Same: 🔑 Takeaways from cIMPACT-NOW Update 8 @OncoAlert
For oncologists &amp; radiation oncologists: here’s what you need to know about the molecular era of meningiomas🧵(1/14)

[Alexandros Papachristofilou @Alex_Papachris]

Carboplatin + involved node radiotherapy (INRT) is now a treatment option for seminoma stage IIA/B in the latest version of the #NCCN Guidelines . Thank you to all patients who took part in #SAKK0110 &amp; #SAKK0118 and to all collaborators. @sakk_ch

[UroToday.com @urotoday]

#PSMAandBeyond2025 212Pb-PSMA vs 225Ac-PSMA: from biology to supply. Presentation by Alfred Morgenstern, PhD. Written coverage by @zklaassen_md @GACancerCenter &gt; https://t.co/oItt7Wz2Sh @PSMAconference @PCFnews

[UroToday.com @urotoday]

#PSMAandBeyond2025: Overview of clinical trials of PSMA RLT in 2025. Presentation by @CalaisJeremie @UCLAHealth. Written coverage by @zklaassen_md @GACancerCenter &gt; https://t.co/9rdoRvkASG @PCFnews @PSMAconference

[Bobby Koneru, MD @KoneruMd]

Potential Impact of LDRT: The addition of LDRT appears to have mitigated some of the degenerative changes typically seen in osteoarthritis progression, suggesting a potential protective or slowing effect on joint deterioration.

[Dr. Luis A. Pérez-Romasanta @LuisAlberto3P]

WOLVERINE Study: 5 trials of 472 oligometastatic prostate cancer patients followed for a median of 41 months.
https://t.co/QNvVhtjd3e a través de @urotoday

[Rashid K. Sayyid @RKSayyid]

Decipher GC for predicting treatment prog in AS pts, adjusted for mpMRI findings (n=338; f/u: 26 mo)
🔹GC score ≥0.45 assoc w/ ⬆️rate of tx prog in both pts with PI-RADS 1-3 & 4-5 lesions (HR: 1.6, p=0.05)
🔹mpMRI PI-RADS 4-5 lesions not assoc w/ rate of tx prog in pts with GC score ≥0.45

📍Findings further support NCCN recs to consider incorporation of Decipher for risk strat of clinically localized PCa pts

@urotoday #SUO24